Latest Clinical Trial Results News

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Entropy Neurodynamics reports compelling Phase 2a results showing oral psilocybin dramatically reduces binge eating episodes and related psychiatric symptoms, supporting advancement of its lead IV psilocin candidate.

Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Cynata Therapeutics is on track to deliver key clinical trial results in mid-2026 while maintaining a solid cash runway supported by an imminent R&D tax rebate and equity facility.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.